A Multicenter Trial of Infusional Etoposide, Doxorubicin, and Vincristine with Cyclophosphamide and Prednisone (EPOCH) in Patients with Relapsed Non-Hodgkin's Lymphoma

Saquinavir enhances the mucosal toxicity

Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma

✍ Joseph A Sparano; Peter H Wiernik; Xiaoping Hu; Catherine Sarta; David H Henry; 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 690 KB

Activity of Rituximab plus Cyclophospham

Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma

✍ Raderer, Markus; Wöhrer, Stefan; Streubel, Berthold; Drach, Johannes; J&aum 📂 Article 📅 2006 🏛 S. Karger AG 🌐 English ⚖ 155 KB

A medical research council randomized tr

A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma : Cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy

✍ Graham M. Mead; Norman M. Bleehen; Anna Gregor; Jill Bullimore; D. Shirley Murre 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

Chemotherapy with etoposide, vincristine

Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma

✍ Gorgun Akpek; Howard K. Koh; Steven Bogen; Carl O'Hara; Francine M. Foss 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

This Phase II study was undertaken to assess the efficacy and toxicity of chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone (EPOCH regimen) in patients with advanced, refractory cutaneous T-cell lymphoma (CTCL). ## METHODS. Fifteen patients were tre

Activity and safety of dose-adjusted inf

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma

✍ Antonino Musolino; Daniela Boggiani; Michele Panebianco; Giovanna Vasini; Stefan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 1 views

Activity and safety of dose-adjusted inf

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma

✍ Alberto Febbri; Alessandro Gozzetti; Luigi Rigacci 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views